Cetuximab efficacy in patients treated routinely in university hospitals

Gastroenterologie Clinique et Biologique

Volumn 31, Issue 11, 2007, Pages 941-949

  Bachet, Jean Baptiste ^a,b,c   Afchain, Pauline ^d   Fermanian, Christophe ^a   Bouchahda, Mohamed ^e   Mitry, Emmanuel ^a,b   Landi, Bruno ^f   André, Thierry ^g   Lièvre, Astrid ^a,b   Louvet, Christophe ^d   Aegerter, Philippe ^a   Levi, Francis ^e   Rougier, Philippe ^a,b  

^a HÔPITAL AMBROISE PARÉ   (France)

^b LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^c ADEBIOPHARM ER48   (France)

^d HÔPITAL SAINT ANTOINE   (France)

^e HÔPITAL PAUL BROUSSE   (France)

^f HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^g HÔPITAL TENON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN;

ACNE; ADULT; AGED; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CANCER SURVIVAL; COLORECTAL CANCER; CONFIDENCE INTERVAL; DIARRHEA; DISEASE ACTIVITY; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEASIBILITY STUDY; FEMALE; HUMAN; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PATIENT COMPLIANCE; PERITONEUM METASTASIS; PROGNOSIS; SURVIVAL TIME; TREATMENT OUTCOME; UNIVERSITY HOSPITAL; WORLD HEALTH ORGANIZATION;

EID: 38149100043     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0399-8320(07)78302-1     Document Type: Article

References (23)

1. Bouvier AM, Remontet L, Jougla E, Launoy G, Grosclaude P, Buemi A, et al. Incidence of gastrointestinal cancers in France. Gastroenterol Clin Biol 2004;28:877-81.
2. Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229-37.
3. Tournigand C, Cervantes A, Figer A, Lledo G, Flesh M, Buyse M, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer-A GERCOR study. J Clin Oncol 2006;24:394-400.
4. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
5. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45.
6. Saltz LB, Meropol NJ, Loehrer PJ, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004;22:1201-8.
7. Ciardiello F, Tortora G. A novel appoach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001;7:2958-70.
8. Penault-Llorca F, Bibeau F, Arnould L, Bralet MP, Rochaix P, Sabourin JC. EGFR expression in colorectal cancer and role in tumorigenesis. Bull Cancer 2005;92:S2-11.
9. Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005;23:1803-10.
10. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457-81.
11. Mantel N, Haenzel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719-48.
12. Cox DR. Regression models and life tables (with discussion). J R Stat Soc B 1972;34:187-220.
13. Vicenzi B, Santini D, Rabitti C, Coppola R, Beomonte Zobel B, Trodella L, et al. Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single phase II trial. Br J Cancer 2006;94:792-7.
14. Gebbia V, Del Prete S, Borsellino N, Ferraù F, Tralongo P, Verderame F, et al. Efficacy and safety of cetuximab/irinotecan in chemotherapy-refractory metastatic colorectal adenocarcinomas: a clinical practice setting, multicenter experience. Clin Colorectal Cancer 2006;5:422-8.
15. Leporrier J, Maurel J, Chiche L, Bara S, Segol P, Launoy G. A population-based study of the incidence, management and prognosis of hepatic metastases from colorectal cancer. Br J Surg 2006:93;465-74.
16. Guyot F, Faivre J, Manfredi S, Meny B, Bonithon-Kopp C, Bouvier AM. Time trends in the treatment and survival of recurrences from colorectal cancer. Ann Oncol 2005;16:756-61.
17. Van Cutsem E, Humblet Y, Gelderblom H, Vermorken JB, Viret F, Glimelius B, et al. Cetuximab dose-escalation study in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): Pharmacokinetic and efficacy data of a randomized study. American Society of Clinical Oncology Gastrointestinal Cancers Symposium 2007:abstract 237.
18. Kohne CH, Cunningham D, Di CF, Glimelius B, Blijham G, Aranda E, et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 2002;13:308-17.
19. Lièvre A, Bachet JB, Lecorre D, Boige V, Landi B, Emile JF, et al. KRAS mutation status is predictive of response to Cetuximab therapy in colorectal cancer. Cancer Res 2006;66:1-5.
20. Lièvre A, Bachet JB, Bouché O, Pezet D, Boige V, Landi B, et al. Les mutations de KRAS dans les cancers colorectaux : facteur prédictif de réponse et de survie sans progression chez les malades traités par anticorps anti-EGFR. Gastroenterol Clin Biol 2007;31:A118.
21. Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, Galais MP, et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer 2007;96: 1166-9.
22. Personeni N, De Schutter J, De Hertogh G, Debiec-Rychter M, Geboes K, Van Cutsem E, et al. Response prediction to cetuximab-based therapy: The role of EGFR copy number by fluorescence in situ hybridization and downstream effectors gene mutations. American Society of Clinical Oncology Gastrointestinal Cancers Symposium 2007:abstract 400.
23. Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the avaibility of flurouracil- leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2005;23:9441-2.